Dr Lisa Lancaster Discusses the Overlap of Sleep Apnea and Lung Diseases

A study from Sweden, the largest of its kind, challenges the standard 24-month milestone as the key point when early relapse is a concern.

Policy strategist Kristi Martin discusses how the Orphan Drug Act reshapes rare disease treatment and drug-pricing challenges.

In a pair of lively debates at the International Stroke Conference 2026, experts from around the world discussed controversies in stroke care.

Nate C. Apathy, PhD, guest editor of AJMC's 15th Health IT special issue, calls for tools to be closely aligned with user needs.

Because evidence gaps in idiopathic pulmonary fibrosis research hinder demonstration of antifibrotic therapies’ impact on patient quality of life (QOL), integrating validated health-related QOL measures into trials is urgently needed.

Experts at ISC 2026 highlighted growing evidence that GLP-1 receptor agonists may reduce stroke risk and support brain health through anti-inflammatory, vascular, and neuroprotective mechanisms.